E-Book | October 9, 2023

Improving Access And Support For Cell And Gene Therapies


In 2022, the FDA approved five new cell and gene therapies (CGT)—and approvals for new therapies are only expected to rise in the years to come. But although CGTs are potentially transformative, their effectiveness is undermined by difficulties with patient access and support, high costs, and a complex pathway to treatment.

Because these cutting-edge therapies require significant patient support, the onus is on sponsor companies, providers, and payers to coordinate care to improve patient access.

After reading this playbook, you’ll understand:

  • The patient access problems that are inherent with CGTs
  • The benefits of data collection and integrated patient support hubs for CGTs
  • The importance of full buy-in and adoption by nurses, providers, payers, and sponsor companies

access the E-Book!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader